SUPN: Supernus Pharmaceuticals, Inc.
About
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Current Value
$35.661 Year Return
Current Value
$35.661 Year Return
Key Details
Market Cap
$1.96B
P/E Ratio
33.26
1Y Stock Return
30.48%
1Y Revenue Growth
6.79%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include SUPN
Stock's related to SUPN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RVLV | 46.01% | $2.35B | +127.64% | 0.00% |
| VCYT | 41.97% | $3.03B | +55.48% | 0.00% |
| EXEL | 40.21% | $9.83B | +62.16% | 0.00% |
| FTNT | 39.55% | $69.59B | +72.67% | 0.00% |
| SWI | 39.14% | $2.22B | +22.97% | 0.00% |
| AZPN | 38.57% | $15.62B | +34.34% | 0.00% |
| BL | 38.49% | $3.61B | +3.02% | 0.00% |
| PEB | 37.38% | $1.48B | +0.08% | 0.33% |
| KRNT | 37.24% | $1.48B | +73.34% | 0.00% |
| LMB | 36.71% | $1.12B | +157.63% | 0.00% |
| VTOL | 36.57% | $1.07B | +42.07% | 0.00% |
| PGC | 36.34% | $646.96M | +45.76% | 0.55% |
| UVSP | 36.21% | $891.91M | +64.40% | 2.76% |
| BY | 36.10% | $1.36B | +51.33% | 1.18% |
| CTBI | 35.97% | $1.06B | +47.55% | 3.18% |
| HTBK | 35.78% | $645.52M | +24.17% | 4.92% |
| RYAM | 35.75% | $596.54M | +189.14% | 0.00% |
| SCL | 35.71% | $1.69B | -6.79% | 2.01% |
| CRNX | 35.53% | $5.12B | +84.27% | 0.00% |
| ANGI | 35.42% | $987.36M | -5.71% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CVS | -0.05% | $70.18B | -18.08% | 4.72% |
| TMUS | -0.09% | $270.63B | +56.92% | 0.83% |
| OLLI | 0.14% | $5.48B | +15.97% | 0.00% |
| NFLX | -0.20% | $372.45B | +83.46% | 0.00% |
| RVP | -0.33% | $17.51M | -46.82% | 0.00% |
| VST | -0.39% | $52.69B | +349.00% | 0.56% |
| TW | 0.39% | $28.66B | +42.39% | 0.29% |
| WING | 0.48% | $9.80B | +45.66% | 0.29% |
| CI | -0.49% | $89.70B | +12.57% | 1.68% |
| ASH | 0.60% | $3.73B | -1.96% | 2.08% |
| MESO | 0.61% | $1.23B | +347.11% | 0.00% |
| VSTO | 0.62% | $2.58B | +71.61% | 0.00% |
| COST | 0.62% | $412.13B | +62.81% | 0.49% |
| UUU | -0.65% | $4.97M | -41.89% | 0.00% |
| GL | -0.71% | $9.18B | -8.60% | 0.86% |
| NEUE | 0.77% | $40.93M | -34.13% | 0.00% |
| RDY | -0.77% | $11.97B | +5.10% | 3.31% |
| OKLO | 0.86% | $2.66B | +111.04% | 0.00% |
| CLLS | 0.88% | $141.30M | -30.99% | 0.00% |
| HLIT | 0.89% | $1.42B | +12.53% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ODP | -20.50% | $777.35M | -46.62% | 0.00% |
| ALAB | -14.24% | $15.10B | +164.39% | 0.00% |
| NVO | -14.04% | $342.62B | -0.15% | 1.40% |
| SMCI | -13.72% | $16.55B | -2.47% | 0.00% |
| SGC | -13.02% | $261.95M | +41.61% | 4.32% |
| NNE | -12.49% | $833.66M | +531.50% | 0.00% |
| IMXI | -12.22% | $651.21M | -1.55% | 0.00% |
| DOGZ | -10.97% | $614.77M | +1,372.26% | 0.00% |
| CMG | -10.58% | $80.02B | +33.62% | 0.00% |
| RDDT | -9.87% | $24.08B | +303.41% | 0.00% |
| AHR | -8.57% | $4.30B | +134.17% | 2.69% |
| RBRK | -7.64% | $8.03B | +38.16% | 0.00% |
| LLY | -6.99% | $692.74B | +23.14% | 0.71% |
| MNR | -6.64% | $1.66B | -10.71% | 15.90% |
| MSB | -5.99% | $337.71M | +30.73% | 5.15% |
| WOW | -5.82% | $434.90M | +18.48% | 0.00% |
| TEM | -5.76% | $8.50B | 0.00% | 0.00% |
| PULM | -5.74% | $19.83M | +202.98% | 0.00% |
| INSG | -5.74% | $157.28M | +540.25% | 0.00% |
| JBI | -5.45% | $1.00B | -31.76% | 0.00% |
ETF's related to SUPN
News
Yahoo
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, U
SeekingAlpha
Supernus Pharmaceuticals is reaping the benefits of its ADHD drug Qelbree, with strong Q3 results and upwardly revised guidance for FY2024. Read more here.
Yahoo
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Third Quarter 2024 Results Key Financial Results Revenue: US$175.7m (up 14...
Yahoo
Supernus Pharmaceuticals Inc (SUPN) reports a 26% revenue increase and raises full-year guidance, driven by robust sales of key products.
Yahoo
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Yahoo
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.